Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus has maintained a Buy rating for Inhibrx Biosciences Inc (INBX) with a price target of $325.00. Analyst Dara Azar, noted for a 27.3% average return, follows a similar Buy rating from LifeSci Capital, which set a price target of $230.00.
In a report released today, Dara Azar from Stifel Nicolaus reiterated a Buy rating on Inhibrx Biosciences Inc, with a price target of $325.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Azar is a 2-star analyst with an average return of 27.3% and a 66.67% success rate.
In a report released on May 11, LifeSci Capital also maintained a Buy rating on the stock with a $230.00 price target.